BEAT vs. IMAC, ANGO, OBIO, INO, UTMD, RCEL, PROF, DCTH, SKIN, and NPCE
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include IMAC (IMAC), AngioDynamics (ANGO), Orchestra BioMed (OBIO), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), AVITA Medical (RCEL), Profound Medical (PROF), Delcath Systems (DCTH), Beauty Health (SKIN), and NeuroPace (NPCE). These companies are all part of the "medical" sector.
IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, IMAC had 6 more articles in the media than BioTelemetry. MarketBeat recorded 8 mentions for IMAC and 2 mentions for BioTelemetry. BioTelemetry's average media sentiment score of 0.07 beat IMAC's score of 0.00 indicating that IMAC is being referred to more favorably in the media.
24.3% of IMAC shares are owned by institutional investors. Comparatively, 7.8% of BioTelemetry shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 20.9% of BioTelemetry shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
BioTelemetry has a net margin of 0.00% compared to BioTelemetry's net margin of -75.40%. BioTelemetry's return on equity of -52.17% beat IMAC's return on equity.
BioTelemetry has a consensus price target of $8.00, suggesting a potential upside of 201.89%. Given IMAC's higher possible upside, analysts plainly believe BioTelemetry is more favorable than IMAC.
IMAC has higher revenue and earnings than BioTelemetry.
IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500.
BioTelemetry received 318 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.56% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote.
Summary
IMAC beats BioTelemetry on 8 of the 14 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
